[{"data":1,"prerenderedAt":183},["ShallowReactive",2],{"drug-ribavirin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":60,"warnings":70,"renal":78,"monitoring":79,"interactions":80,"review":81,"examples":84,"atc":85,"iran":87,"usApproval":119,"links":125,"populations":141},"ribavirin",1,{"fa":7,"en":8},"ریباویرین","Ribavirin","anti-infectives",{"fa":11,"en":12},"آنالوگ نوکلئوزید (ضدویروس)","Nucleoside analogue antiviral",[14],{"name":15,"market":16},"Rebetol","US",[18,19,7],"rebetol","ربتول",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"cap-200","capsule","oral","200 mg capsule",{"amount":27,"unit":28,"perUnit":23,"scored":29},200,"mg",false,[16],[32],{"source":33,"section":34},"fda-ribavirin","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":51},"hcv","hepatitis-c",{"fa":40,"en":41},"هپاتیت C مزمن (فقط همراه اینترفرون) — ۸۰۰ تا ۱۴۰۰ mg\u002Fروز در دو دوز بر اساس وزن","Chronic hepatitis C (only with interferon) — 800–1400 mg\u002Fday in two doses by weight",{"minAge":43},{"value":44,"unit":45},18,"year","notCalculated",{"reason":48},{"fa":49,"en":50},"دوز از جدول وزنی برچسب (همراه PegIntron یا Intron A)؛ با غذا؛ کپسول باز یا شکسته نشود. به‌تنهایی برای HCV مؤثر نیست. در کم‌خونی یا عوارض طبق جدول ۴ کاهش.","Dose from the label weight table (with PegIntron or Intron A); with food; do not open or crush. Not effective alone for HCV. Reduce for anaemia\u002Fadverse reactions per Table 4.",[52,54,56,58],{"source":33,"section":53},"2.2",{"source":33,"section":55},"2.3",{"source":33,"section":57},"2.1",{"source":33,"section":59},"2.5",[61],{"id":62,"severity":63,"text":64,"refs":67},"ci","block",{"fa":65,"en":66},"بارداری و همسر مرد زن باردار؛ هموگلوبینوپاتی (تالاسمی ماژور، سیکل‌سل)؛ هپاتیت خودایمنی؛ نارسایی کبد جبران‌نشده؛ ClCr زیر ۵۰؛ دیدانوزین.","Pregnancy and male partners of pregnant women; haemoglobinopathies (thalassaemia major, sickle-cell); autoimmune hepatitis; decompensated liver disease; CrCl \u003C50; didanosine.",[68],{"source":33,"section":69},"4",[71],{"text":72,"refs":75},{"fa":73,"en":74},"هشدار جعبه‌ای: سمیت شدید جنینی (پیشگیری تا ۶ ماه پس از درمان در زن و مرد)؛ کم‌خونی همولیتیک؛ به‌تنهایی بی‌اثر.","Boxed warning: severe embryo-fetal toxicity (contraception until 6 months after treatment for women and men); haemolytic anaemia; ineffective alone.",[76],{"source":33,"section":77},"Boxed Warning",[],[],[],{"status":82,"reviewer":83,"date":83},"unverified",null,[],[86],"J05AP01",{"status":88,"forms":89,"refs":114},"registered",[90,94,98,102,106,110],{"code":91,"en":92,"fa":93},"20076","RIBAVIRIN 100MG AMP","آمپول ریباویرین ۱۰۰ میلی‌گرم",{"code":95,"en":96,"fa":97},"01879","RIBAVIRIN 100MG CAP","کپسول ریباویرین ۱۰۰ میلی‌گرم",{"code":99,"en":100,"fa":101},"01880","RIBAVIRIN 100MG TAB","قرص ریباویرین ۱۰۰ میلی‌گرم",{"code":103,"en":104,"fa":105},"01891","RIBAVIRIN 200MG CAP","کپسول ریباویرین ۲۰۰ میلی‌گرم",{"code":107,"en":108,"fa":109},"01881","RIBAVIRIN 200MG TAB","قرص ریباویرین ۲۰۰ میلی‌گرم",{"code":111,"en":112,"fa":113},"52656","RIBAVIRIN TABLET ORAL 600 mg","قرص ریباویرین ۶۰۰ میلی‌گرم",[115],{"source":116,"section":117,"url":118},"darooyab-generic","G-1199\u002FRibavirin","https:\u002F\u002Fwww.darooyab.ir\u002FG-1199\u002FRibavirin",{"kind":120,"refs":121,"id":124},"ANDA",[122],{"source":33,"section":123},"SPL approval \u002F marketing category","ANDA079117",[126,129,133,136,139],{"kind":127,"url":128,"label":124},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=079117",{"kind":130,"url":131,"label":132},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=35f99f76-f2ef-4a81-91ff-285419664be3","FDA Ribavirin caps",{"kind":134,"url":135,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa605018.html",{"kind":137,"url":138,"label":86},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AP01",{"kind":140,"url":118,"label":8},"darooyab",{"pregnancy":142,"lactation":150,"pediatric":159,"geriatric":167,"reproductive":175},{"level":143,"text":144,"quote":147,"refs":148},"contraindicated",{"fa":145,"en":146},"برچسب: در بارداری منع مصرف دارد.","Label: contraindicated in pregnancy.","Ribavirin capsules combination therapy is contraindicated in: pregnancy.",[149],{"source":33,"section":69},{"level":151,"text":152,"quote":155,"refs":156},"caution",{"fa":153,"en":154},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of ribavirin in human milk or the effects on the breastfed infant or milk production.",[157],{"source":33,"section":158},"8.2",{"level":151,"text":160,"quote":163,"refs":164},{"fa":161,"en":162},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of ribavirin in combination with PegIntron has not been established in pediatric patients below the age of 3 years.",[165],{"source":33,"section":166},"8.4",{"level":151,"text":168,"quote":171,"refs":172},{"fa":169,"en":170},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, ribavirin capsules should be administered to elderly patients cautiously, starting at the lower end of the dosing range, reflecting the greater frequency of decreased hepatic and cardiac function, and of concomitant disease or other drug therapy.",[173],{"source":33,"section":174},"8.5",{"level":151,"text":176,"quote":179,"refs":180},{"fa":177,"en":178},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Female patients of reproductive potential should use effective contraception during treatment and for 9 months post-therapy.",[181],{"source":33,"section":182},"8.3",1792191564365]